



## **EUSA PHARMA ACQUIRES INNOCOLL'S ANTIBIOTIC AND PAIN CONTROL PRODUCTS AND EUROPEAN SALES AND MARKETING INFRASTRUCTURE**

**- Acquisition expands EUSA's critical care and pain control product portfolio -**

**- EUSA's pan-European commercial infrastructure extended to over 20 countries -**

**Doylestown PA, USA and Oxford, UK - 23 August 2007** – EUSA Pharma Inc (“EUSA”), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the acquisition of the assets of Innocoll Inc (“Innocoll”). These assets include worldwide rights to the antibiotic surgical implant Collatamp® G for all markets except the USA, and similar rights to the late-stage development products Collatamp® G topical and implantable CollaRx® bupivacaine for post-surgery pain control. The acquisition also grants EUSA an option to the US rights for CollaRx bupivacaine. In addition, Innocoll will transfer to EUSA its pan-European sales and marketing infrastructure, which has a presence in over 20 European territories, as well as its distribution network covering more than 25 further countries around the world. As part of the agreement, Innocoll will continue to manufacture and supply the products to EUSA, and will progress the development of the late-stage clinical programmes. In return, EUSA will make an upfront payment, pay development, regulatory and sales performance milestone fees and take an equity investment in Innocoll's parent company.

“The acquisition of these critical care and pain control products fits our focused specialty pharmaceutical business model perfectly, and by retaining an interest in the US rights we are further progressing towards our goal of becoming a leading transatlantic specialty company,” said **Bryan Morton, Chief Executive of EUSA Pharma**. “The addition of a well established pan-European sales and marketing team to our existing EU infrastructure will accelerate our growth, making EUSA a significant player in its field and increasingly a partner-of-choice for companies seeking genuine transatlantic commercial expertise.”

Commenting on the acquisition, **Rolf Stahel, Chairman of EUSA Pharma**, said, “Today's news marks another important milestone in the rapid growth of EUSA. Less than 18 months after the founding of the Company the team has completed three significant acquisitions, and made great progress in building the foundations of a world-class specialty pharmaceutical business.”

**Dr Michael Myers, President and CEO of Innocoll Inc** said: “We look forward to a productive future in our partnership with EUSA and to the continuing success of these important specialty products.”

### **About Collatamp® G**

The Collatamp® G surgical implant is based on Innocoll's proprietary CollaRx® collagen sponge technology, which is designed for site-specific delivery of pharmaceuticals, particularly antibiotics and anaesthetics. The implant is a leave-behind biodegradable collagen matrix impregnated with the broad-spectrum antibiotic gentamicin, which is indicated for the treatment and prevention of post-surgical acquired infection. The product, which has significant growth potential in a major market segment, is approved for use in approximately 50 countries in Europe, Latin America, Middle

East, Africa and Asia and is marketed under the trade names COLLATAMP® G, COLLATAMP® EG, SULMYCIN® IMPLANT, GARAMYCIN® SCHWAMM, DURACOL®, DURACOLL®, GENTACOL®, GENTACOLL®, GARACOL®, GARACOLL®, and CRONOCOL®. The implant has successfully completed 20 clinical studies in over 6,000 subjects, and with an IND filed with the FDA in July 2007, is poised to enter phase III studies in the USA in the coming months.

### **About Collatamp® G topical and CollaRx® bupivacaine implant**

The topical application of Collatamp® G comprises a gentamicin impregnated collagen sponge that combines an active dressing with local antibiotic delivery, for the treatment or prevention of infected skin ulcers, such as those caused on the legs and feet by diabetes. Currently, both prophylactic and therapeutic applications are in phase II clinical development.

The CollaRx® bupivacaine surgical implant is designed to provide local post-operative pain relief and thereby also reduce opioid dependency. The implant is a leave-behind collagen matrix loaded with the local anaesthetic bupivacaine, which has broad applicability across a wide range of general and orthopaedic surgery. The product is currently undergoing phase II clinical testing.

### **About EUSA Pharma**

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has 5 products on the market, including Erwinase® and Kidrolase® for the treatment of acute lymphoblastic leukemia, and Rapydan™, a rapid-onset anaesthetic patch for which EUSA Pharma expects to receive Europe-wide approval later this year.

Supported by leading life science investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest, EUSA Pharma has raised over \$225 million and completed three significant acquisitions since its founding in May 2006. Maintaining its focus on oncology, pain control and critical care, the company is currently seeking partners for the non-core development programmes it gained as part of its recent acquisitions, in Alzheimer's disease, multiple sclerosis, anti-psychosis and inflammatory diseases.

For more information on the company please visit [www.eusapharma.com](http://www.eusapharma.com).

### **Contacts**

#### **EUSA Pharma**

Bryan Morton, Chief Executive +44 (0) 1865 784 255

#### **EUSA Pharma US**

Paul Barone, VP, Business Development +1 (215) 230 9620

#### **Financial Dynamics**

Julia Phillips / Emma Thompson +44 (0) 20 7831 3113